Option Care Health Inc (NASDAQ: OPCH) saw its stock soar 5.08% during Wednesday's intraday trading session, following a notable upgrade from UBS and the release of impressive first-quarter 2025 financial results.
UBS raised its rating on Option Care Health from Neutral to Buy and increased its price target from $38 to $40. This upgrade comes on the heels of the company's strong Q1 2025 earnings report, which exceeded analyst expectations. Option Care Health reported revenue of $1.33 billion, up 16% year-over-year and 6% above analyst estimates. Earnings per share came in at $0.28, surpassing analyst projections by 3.2%.
The positive sentiment was further reinforced by Barrington Research, which maintained its Outperform rating on the stock. With an average analyst rating of Buy and a mean price target of $34.67, Option Care Health appears well-positioned for future growth. The company's robust performance in the face of rising healthcare demand and its ability to exceed market expectations have clearly resonated with investors, driving the significant stock price increase observed today.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.